Capsaicin dermal patch - Grunenthal

Drug Profile

Capsaicin dermal patch - Grunenthal

Alternative Names: 8% capsaicin patch - NeurogesX; Capsaicin; NGX-4010; Qutenza; Transacin; Transdolor™ Pain Treatment System

Latest Information Update: 20 Nov 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator NeurogesX
  • Developer Astellas Pharma Europe Ltd; NeurogesX
  • Class Antipruritics; Catechols; Local anaesthetics; Monounsaturated fatty acids; Non-opioid analgesics; Polyunsaturated alkamides; Small molecules
  • Mechanism of Action Substance P inhibitors; TRPV1 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuropathic pain; Postherpetic neuralgia
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Neuropathic pain; Postherpetic neuralgia
  • Registered Diabetic neuropathies
  • No development reported Postoperative pain

Most Recent Events

  • 14 Nov 2018 Capsaicin dermal patch licensed to Averitas Pharma in USA
  • 05 Nov 2018 Capsaicin dermal patch is available for licensing in Asia, Australia as of 05 Nov 2018
  • 05 Nov 2018 Grunenthal acquires capsaicin dermal patch from Acorda Therapeutics
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top